IO Biotech is a Copenhagen-based clinical-stage biopharmaceutical company developing immune-modulating anti-cancer therapies built on its proprietary T-win® technology. The T-win platform enables activation of T cells that are specific for immune-suppressive molecules. Its pipeline includes two lead compounds targeting IDO and PD-L1 that are in clinical development and several additional candidates in pre-clinical phases. The company is led by founder and CEO Mai-Britt Zocca, PhD. IO Biotech intends to use proceeds from its recent financing to fund clinical trials across early and late-stage immuno-oncology programs, including a large randomized trial of IO102 and IO103 with anti-PD-1 monoclonal antibodies in metastatic melanoma. The U.S. FDA granted breakthrough therapy designation on December 15, 2020 for the IO102/IO103 plus anti-PD-1 combination in unresectable or metastatic melanoma.

Total raised

$155M

Funding rounds

1

Latest round

Series B

Latest activity

Jan 2021